secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2022-02-23T23:59:59+00:00
Accession:  0000917520-22-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra Q4 revenue $405.5M (+8.3% organic); adj EPS $0.84 flat; guides FY2022 adj EPS $3.27-3.35
--------------------------------------------------------------------------------

- Q4 reported revenue $405.5M (+4.3% reported, +8.3% organic); GAAP EPS $0.53 vs $1.09 (prior-year $59.2M tax benefit); adjusted EPS $0.84 flat.
- Full-year 2021 revenue $1,542.4M (+12.4% reported, +14.2% organic); GAAP EPS $1.98 vs $1.57; adjusted EPS $3.18 vs $2.45.
- Q4 Codman Specialty Surgical organic growth +9.0%; Tissue Technologies organic +6.7%.
- FY2022 guidance: revenue $1,580-1,600M (organic +3.5-5%); adjusted EPS $3.27-3.35; Q1 revenue $357-365M, adj EPS $0.67-0.71.
- Entered $125M accelerated share repurchase on Jan 12, 2022, expected to complete in H1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752022000007/0000917520-22-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752022000007/iart-20220223.htm
  HTML page:      https://secwatch.observer/filing/0000917520-22-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer